Liquidia Corporation (NASDAQ:LQDA) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Liquidia Corporation (NASDAQ:LQDA) have been given a consensus recommendation of “Moderate Buy” by the eleven research firms that are presently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, seven have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $39.6667.

Several analysts recently issued reports on LQDA shares. HC Wainwright lifted their price target on shares of Liquidia from $35.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. Wells Fargo & Company started coverage on shares of Liquidia in a research report on Monday, October 20th. They issued an “overweight” rating and a $31.00 price target on the stock. Needham & Company LLC increased their price objective on Liquidia from $36.00 to $52.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Raymond James Financial reaffirmed a “strong-buy” rating and set a $47.00 target price on shares of Liquidia in a research report on Tuesday, November 4th. Finally, Wall Street Zen lowered Liquidia from a “buy” rating to a “hold” rating in a research report on Sunday, January 18th.

Insider Activity at Liquidia

In other Liquidia news, General Counsel Russell Schundler sold 27,289 shares of Liquidia stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $37.43, for a total transaction of $1,021,427.27. Following the transaction, the general counsel owned 579,394 shares of the company’s stock, valued at $21,686,717.42. This trade represents a 4.50% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Michael Kaseta sold 36,932 shares of the company’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $37.43, for a total value of $1,382,364.76. Following the completion of the transaction, the chief financial officer directly owned 350,919 shares of the company’s stock, valued at approximately $13,134,898.17. This represents a 9.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 252,476 shares of company stock valued at $9,173,435 over the last three months. Insiders own 26.50% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Federated Hermes Inc. bought a new stake in shares of Liquidia during the 3rd quarter valued at about $7,290,000. Caprock Group LLC bought a new position in shares of Liquidia in the 3rd quarter worth approximately $37,114,000. Campbell & CO Investment Adviser LLC purchased a new position in shares of Liquidia in the 3rd quarter valued at approximately $2,026,000. XTX Topco Ltd bought a new stake in shares of Liquidia during the second quarter valued at approximately $1,485,000. Finally, Tyro Capital Management LLC bought a new position in Liquidia in the second quarter worth $15,473,000. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Liquidia Stock Down 2.2%

Shares of NASDAQ:LQDA opened at $38.20 on Friday. The company has a debt-to-equity ratio of 6.19, a quick ratio of 1.96 and a current ratio of 2.20. Liquidia has a 52-week low of $11.26 and a 52-week high of $46.67. The business’s 50 day simple moving average is $37.40 and its two-hundred day simple moving average is $29.74. The firm has a market cap of $3.32 billion, a P/E ratio of -26.53, a PEG ratio of 1.07 and a beta of 0.46.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).